We updated the Mycophenolic acid Pathway in collaboration with Kinjal
Sanghavi and Dr. Vishal Lamba from the University of Minnesota.
Mycophenolic Acid (MPA) is an
immunosuppressive agent and is indicated as prophylactic agent in patients
receiving allogeneic renal, cardiac or hepatic transplants.
This PharmGKB pathway
describes the steps and metabolites involved in the pharmacokinetic
of mycophenolate mofetil, the prodrug of MPA.
The target of MPA is
the inosine monophosphate dehydrogenase, which is an important rate limiting enzyme involved in
purine synthesis. The pharmacodynamic section highlights several mechanisms of action of MPA.
Genetic variants within genes
involved in MPA uptake and metabolism, and in its targets have been reported to
affect MPA response in patients undergoing transplantation. For more
information read the entire pathway description of the Mycophenolic acid Pathway at PharmGKB.
